# EDGAR Filing Document

**Accession Number:** 0001071739
**File Stem:** 0001071739-26-000031
**Filing Date:** 2026-2
**Character Count:** 83705
**Document Hash:** 92bb723c6d90b7ced9072eb5726207ba
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001071739-26-000031.hdr.sgml**: 20260206

**ACCESSION NUMBER**: 0001071739-26-000031

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 22

**CONFORMED PERIOD OF REPORT**: 20260206

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260206

**DATE AS OF CHANGE**: 20260205

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CENTENE CORP
- **CENTRAL INDEX KEY:** 0001071739
- **STANDARD INDUSTRIAL CLASSIFICATION:** HOSPITAL & MEDICAL SERVICE PLANS [6324]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 041406317
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-31826
- **FILM NUMBER:** 26604832

**BUSINESS ADDRESS:**
- **STREET 1:** 7700 FORSYTH BLVD.
- **CITY:** ST LOUIS
- **STATE:** MO
- **ZIP:** 63105
- **BUSINESS PHONE:** 3147254477

**MAIL ADDRESS:**
- **STREET 1:** 7700 FORSYTH BLVD.
- **CITY:** ST LOUIS
- **STATE:** MO
- **ZIP:** 63105

?xml version='1.0' encoding='ASCII'? cnc-20260206

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, D.C. 20549** 

**FORM 8-K** 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 6, 2026

**CENTENE CORPORATION** 

(Exact Name of Registrant as Specified in Charter)

Delaware 001-31826 42-1406317 <br> (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.)

---

| | | |
|:---|:---|:---|
| 7700 Forsyth Boulevard, | 7700 Forsyth Boulevard, | |
| St. Louis, | Missouri | 63105 |
| (Address of Principal Executive Offices) | (Address of Principal Executive Offices) | (Zip Code) |

---

Registrant's telephone number, including area code: (314) 725-4477

(Former Name or Former Address, if Changed Since Last Report): N/A

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐&nbsp;&nbsp;&nbsp;&nbsp;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐&nbsp;&nbsp;&nbsp;&nbsp;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐&nbsp;&nbsp;&nbsp;&nbsp;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common stock, $0.001 Par Value | CNC | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION** 

(a) On February 6, 2026, we issued a press release announcing our financial results for the fourth quarter and year ended December 31, 2025. The full text of the press release is included as Exhibit 99.1 to this report. The information contained in the website cited in the press release is not a part of this report. Additionally, we have included a presentation outlining details of our full year 2026 guidance.

The information contained in this Form 8-K, Exhibit 99.1 and Exhibit 99.2 attached hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section. Nor shall such information or exhibit be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as expressly set forth by specific reference in such a filing.

**ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS** 

(d) Exhibits

The following exhibits relating to Item 2.02 shall be deemed to be furnished and not filed:

&nbsp;&nbsp;&nbsp;&nbsp;99.1 Press release of Centene Corporation issued February 6, 2026, as to financial results for the fourth quarter and year ended December 31, 2025

&nbsp;&nbsp;&nbsp;&nbsp;99.2 Centene Corporation 2026 Guidance Presentation

------

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 99.1\* | <u>[Press release of Centene Corporation issued February 6, 2026 as to financial results for the fourth quarter and year ended December 31, 2025](a20260206ex991pressrelease.htm)</u> |
| 99.2\* | <u>[Centene Corporation 2026 Guidance Presentation](centenecorporation2026gu.htm)</u> |
| 104 | Cover page information from Centene Corporation's Current Report on Form 8-K filed on February 6, 2026 formatted in Inline Extensible Business Reporting Language (iXBRL). |

---

\* The press release and presentation are being furnished pursuant to Item 2.02, and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange of 1934, as amended.

------

**SIGNATURE** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | **CENTENE CORPORATION** | **CENTENE CORPORATION** |
| Date: | February 6, 2026 | By: | /s/ ANDREW L. ASHER |
|  |  |  | Andrew L. Asher<br>Executive Vice President & Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;** 

**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;** ![centenelogoa60.jpg](centenelogoa60.jpg)

**N E W S R E L E A S E&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;** 

---

| | | |
|:---|:---|:---|
| Contact: | Investor Relations Inquiries | Media Inquiries |
|  | Jennifer Gilligan | Sara Garland |
|  | Senior Vice President, Finance & Investor Relations | Chief Communications Officer |
|  | (212) 549-1306 | (314) 445-0790 |

---

**FOR IMMEDIATE RELEASE**

 **CENTENE CORPORATION REPORTS 2025 RESULTS AND ANNOUNCES 2026 GUIDANCE**

**-- 2025 Full Year GAAP Diluted Loss Per Share of $(13.53); Adjusted Diluted Earnings Per Share of $2.08 --**

**-- 2026 Adjusted Diluted Earnings Per Share Guidance of Greater than $3.00 --**

**• Consolidated HBR of 94.3% in the fourth quarter of 2025, which includes a Commercial HBR of 95.4% that was 100 basis points higher than expectations driven by net out of period items.**

**• Medicaid HBR of 93.0% in the fourth quarter of 2025, reflecting continued progress and representing 40 basis points of sequential improvement compared to the third quarter.**

**• Fundamental fourth quarter 2025 trend was consistent with expectations in Medicaid and Medicare Advantage, and slightly favorable in Marketplace and Medicare PDP.**

**• Strong SG&A management throughout 2025 with an adjusted SG&A expense ratio of 7.4% for the full year.**

ST. LOUIS, February 6, 2026 -- Centene Corporation (NYSE: CNC) (the Company) announced today its financial results for the fourth quarter and year ended December 31, 2025. In summary, the 2025 fourth quarter and full year results were as follows:

---

| | | | |
|:---|:---|:---|:---|
| **2025 Results** | **2025 Results** | **2025 Results** | **2025 Results** |
| | | **Q4** | **Full Year** |
| &nbsp;&nbsp;Total revenues (in millions) | &nbsp;&nbsp;Total revenues (in millions) | $49725 | $194777 |
| &nbsp;&nbsp;Premium and service revenues (in millions) | &nbsp;&nbsp;Premium and service revenues (in millions) | $44727 | $174581 |
| &nbsp;&nbsp;Health benefits ratio | &nbsp;&nbsp;Health benefits ratio | 94.3% | 91.9% |
| &nbsp;&nbsp;SG&A expense ratio | &nbsp;&nbsp;SG&A expense ratio | 7.5% | 7.4% |
| &nbsp;&nbsp;Adjusted SG&A expense ratio <sup>(1)</sup> | &nbsp;&nbsp;Adjusted SG&A expense ratio <sup>(1)</sup> | 7.5% | 7.4% |
| &nbsp;&nbsp;GAAP diluted loss per share | &nbsp;&nbsp;GAAP diluted loss per share | $(2.24) | $(13.53) |
| &nbsp;&nbsp;Adjusted diluted earnings (loss) per share <sup>(1)</sup> | &nbsp;&nbsp;Adjusted diluted earnings (loss) per share <sup>(1)</sup> | $(1.19) | $2.08 |
| &nbsp;&nbsp;Total cash flow provided by operations (in millions) | &nbsp;&nbsp;Total cash flow provided by operations (in millions) | $437 | $5088 |
| <sup>(1)</sup> | Represents a non-GAAP financial measure. A full reconciliation of the adjusted diluted earnings (loss) per share and adjusted selling, general and administrative (SG&A) expenses is shown in the Non-GAAP Financial Presentation section of this release. | Represents a non-GAAP financial measure. A full reconciliation of the adjusted diluted earnings (loss) per share and adjusted selling, general and administrative (SG&A) expenses is shown in the Non-GAAP Financial Presentation section of this release. | Represents a non-GAAP financial measure. A full reconciliation of the adjusted diluted earnings (loss) per share and adjusted selling, general and administrative (SG&A) expenses is shown in the Non-GAAP Financial Presentation section of this release. |

---

"We are pleased to end a challenging year carrying positive momentum from the extensive and decisive actions taken in the back half of 2025 with the goal of restoring Marketplace profitability and stabilizing the trajectory of our Medicaid business," said Chief Executive Officer of Centene, Sarah M. London. "As we look to 2026, we are positioned to deliver meaningful margin improvement and renewed adjusted diluted EPS growth. We expect full year 2026 adjusted diluted EPS to be greater than $3.00, marking important progress toward restoring the enterprise's embedded earnings power all while continuing to work to provide access to affordable, high-quality care for our members."

------

**Other Events**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In December 2025, Centene signed a definitive agreement to divest the remaining Magellan Health businesses. As a result, the Company recorded non-cash impairment charges associated with the pending divestiture totaling $513 million, or $389 million after-tax.

**Awards & Community Engagement**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In November, the Centene Foundation and five Centene subsidiaries – Buckeye Health Plan, Sunshine Health, Carolina Complete Health, Meridian Health Plan of Illinois, and Superior HealthPlan – announced a number of contributions to support food banks and community-based organizations addressing food insecurity following disruptions to the Supplemental Nutrition Assistance Program (SNAP) and the Special Supplemental Nutrition Program for Women, Infants, and Children (WIC).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In November, Health Net, a Centene subsidiary, announced the renewal of its partnership with LA Family Housing to support initiatives aimed at increasing access to stable, affordable housing and to build infrastructure for whole-person health for individuals experiencing homelessness in parts of Los Angeles County.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In October, Iowa Total Care, a Centene subsidiary, in partnership with Central Iowa Shelter & Services, announced the opening of a new Empowerment Command Center and Affordable Housing Project, aimed at providing essential services, including job training, health and wellness services, housing support, and more, to residents of Wapello County, Iowa.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In October, Home State Health, a Centene subsidiary, launched a Foster Care Center of Excellence (FCCOE) in partnership with Jordan Valley Community Health Center in Missouri. The pediatric clinic provides comprehensive care – including behavioral and physical health, vision, and dental services – for children and youth. Centene's FCCOEs are also operational in Texas, Washington, and Oklahoma.

**Membership**

The following table sets forth membership by line of business:

---

| | | | |
|:---|:---|:---|:---|
| | | **December 31,** | **December 31,** |
| | | **2025** | **2024** |
| Traditional Medicaid <sup>(1)</sup> | Traditional Medicaid <sup>(1)</sup> | 10932600 | 11408100 |
| High Acuity Medicaid <sup>(2)</sup> | High Acuity Medicaid <sup>(2)</sup> | 1585800 | 1595400 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Medicaid | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Medicaid | 12518400 | 13003500 |
| Marketplace | Marketplace | 5541400 | 4382100 |
| Individual and Commercial Group <sup>(3)</sup> | Individual and Commercial Group <sup>(3)</sup> | 452500 | 431400 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Commercial | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Commercial | 5993900 | 4813500 |
| Medicare <sup>(4)</sup> | Medicare <sup>(4)</sup> | 1002600 | 1110900 |
| Medicare Prescription Drug Plan (PDP) | Medicare Prescription Drug Plan (PDP) | 8118600 | 6925700 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total at-risk membership | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total at-risk membership | 27633500 | 25853600 |
| TRICARE eligibles | TRICARE eligibles |  | 2747000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | 27633500 | 28600600 |
| <sup>(1)</sup> | Membership includes Temporary Assistance for Needy Families (TANF), Medicaid Expansion, Children's Health Insurance Program (CHIP), Foster Care and Behavioral Health. | Membership includes Temporary Assistance for Needy Families (TANF), Medicaid Expansion, Children's Health Insurance Program (CHIP), Foster Care and Behavioral Health. | Membership includes Temporary Assistance for Needy Families (TANF), Medicaid Expansion, Children's Health Insurance Program (CHIP), Foster Care and Behavioral Health. |
| <sup>(2)</sup> | Membership includes Aged, Blind, or Disabled (ABD), Intellectual and Developmental Disabilities (IDD), Long-Term Services and Supports (LTSS) and Medicare-Medicaid Plans (MMP) Duals. | Membership includes Aged, Blind, or Disabled (ABD), Intellectual and Developmental Disabilities (IDD), Long-Term Services and Supports (LTSS) and Medicare-Medicaid Plans (MMP) Duals. | Membership includes Aged, Blind, or Disabled (ABD), Intellectual and Developmental Disabilities (IDD), Long-Term Services and Supports (LTSS) and Medicare-Medicaid Plans (MMP) Duals. |
| <sup>(3)</sup> | Membership includes Commercial Group, Individual Coverage Health Reimbursement Arrangement (ICHRA) and Other Off-Exchange Individual. | Membership includes Commercial Group, Individual Coverage Health Reimbursement Arrangement (ICHRA) and Other Off-Exchange Individual. | Membership includes Commercial Group, Individual Coverage Health Reimbursement Arrangement (ICHRA) and Other Off-Exchange Individual. |
| <sup>(4)</sup> | Membership includes Medicare Advantage and Medicare Supplement. | Membership includes Medicare Advantage and Medicare Supplement. | Membership includes Medicare Advantage and Medicare Supplement. |

---

------

**Premium and Service Revenues**

The following table sets forth supplemental revenue information ($ in millions):

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| | | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | | **2025** | **2024** | **% Change** | **2025** | **2024** | **% Change** |
| Medicaid | Medicaid | $23045 | $20825 | 11% | $90238 | $83851 | 8% |
| Commercial | Commercial | 10792 | 8723 | 24% | 42003 | 33702 | 25% |
| Medicare <sup>(1)</sup> | Medicare <sup>(1)</sup> | 9610 | 5476 | 75% | 37210 | 23032 | 62% |
| Other | Other | 1280 | 1272 | 1% | 5130 | 4920 | 4% |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total premium and service revenues | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total premium and service revenues | $44727 | $36296 | 23% | $174581 | $145505 | 20% |
| <sup>(1)</sup> | Medicare includes Medicare Advantage, Medicare PDP and Medicare Supplement. | Medicare includes Medicare Advantage, Medicare PDP and Medicare Supplement. | Medicare includes Medicare Advantage, Medicare PDP and Medicare Supplement. | Medicare includes Medicare Advantage, Medicare PDP and Medicare Supplement. | Medicare includes Medicare Advantage, Medicare PDP and Medicare Supplement. | Medicare includes Medicare Advantage, Medicare PDP and Medicare Supplement. | Medicare includes Medicare Advantage, Medicare PDP and Medicare Supplement. |

---

**Statement of Operations: Three Months Ended December 31, 2025**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• For the fourth quarter of 2025, premium and service revenues increased 23% to $44.7 billion from $36.3 billion in the comparable period of 2024. The increase was primarily driven by premium yield and membership growth in the PDP business, overall market growth in the Marketplace business, as well as rate increases and state-directed payments in the Medicaid business, partially offset by lower Medicaid membership.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Health benefits ratio (HBR) of 94.3% for the fourth quarter of 2025 represents an increase from 89.6% in the comparable period in 2024. The increase was primarily driven by the impact of higher Marketplace morbidity in 2025 on medical costs and program changes in the PDP business as a result of the Inflation Reduction Act (IRA) compared to the fourth quarter of 2024. The Medicaid HBR decreased by 40 basis points, primarily driven by rate and revenue increases, partially offset by higher medical costs largely related to behavioral health and home health.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The SG&A expense ratio was 7.5% for the fourth quarter of 2025, compared to 8.9% in the fourth quarter of 2024. The adjusted SG&A expense ratio was 7.5% for the fourth quarter of 2025, compared to 8.9% in the fourth quarter of 2024. The decreases were primarily driven by continued discipline, leveraging of expenses over higher revenues and growth in the PDP business, which operates at a meaningfully lower SG&A expense ratio as compared to the overall company. The decreases were partially offset by growth in the Marketplace business, which operates at a meaningfully higher SG&A expense ratio.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The effective tax rate was 28.7% for the fourth quarter of 2025, compared to 19.2% in the fourth quarter of 2024. The effective tax rate for the fourth quarter of 2025 reflects the impact of the Magellan Health impairment and the release of state uncertain tax position liabilities resulting from statute of limitations expirations. For the fourth quarter of 2025, our effective tax rate on adjusted earnings was 32.1%, compared to 20.7% in the fourth quarter of 2024. The adjusted effective tax rate for the fourth quarter of 2025 reflects the release of state uncertain tax position liabilities resulting from statute of limitations expirations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In December 2025, Centene signed a definitive agreement to divest the remaining Magellan Health businesses. As a result, the Company recorded impairment charges associated with the pending divestiture totaling $513 million, or $389 million after-tax.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GAAP diluted loss per share of $(2.24) for the fourth quarter of 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted diluted loss per share of $(1.19) for the fourth quarter of 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash flow provided by operations for the fourth quarter of 2025 was $437 million, primarily driven by the timing of pharmacy rebates, CMS and state remittances, as well as claims and other payments.

------

**Statement of Operations: Year Ended December 31, 2025**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• For the full year 2025, premium and service revenues increased 20% to $174.6 billion from $145.5 billion in the comparable period of 2024 primarily driven by premium yield and membership growth in the PDP business, overall market growth in the Marketplace business, and rate increases in the Medicaid business, partially offset by lower Medicaid membership and lower Marketplace estimated risk adjustment revenue. The full year 2024 benefited from outperformance in Marketplace risk adjustment for the 2023 benefit year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• HBR of 91.9% for the full year 2025 represents an increase compared to 88.3% in 2024. The increase was primarily driven by lower Marketplace estimated risk adjustment revenue, increased Marketplace medical costs, program changes in the PDP business as a result of the IRA and higher medical costs in Medicaid driven primarily by behavioral health, home health and high-cost drugs, partially offset by Medicaid rate increases.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The SG&A expense ratio was 7.4% for the full year 2025, compared to 8.5% for the full year 2024. The adjusted SG&A expense ratio was 7.4% for the full year 2025, compared to 8.5% for the full year 2024. The decreases were primarily driven by continued discipline, leveraging of expenses over higher revenues and growth in the PDP business, which operates at a meaningfully lower SG&A expense ratio as compared to the overall company. The decreases were partially offset by growth in the Marketplace business, which operates at a meaningfully higher SG&A expense ratio.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• As a result of market conditions in July 2025, including the One Big Beautiful Bill Act and the decline in the Company's stock price, we performed a quantitative impairment analysis during the third quarter to determine whether goodwill was impaired. In October 2025, we completed our quantitative goodwill impairment analysis and recorded a non-cash goodwill impairment of $6.7 billion in the third quarter of 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The effective tax rate was 0.8% for 2025, compared to 22.6% for 2024. The effective tax rate for 2025 reflects the non-deductible nature of the goodwill impairment and the release of state uncertain tax position liabilities resulting from statute of limitations expirations. The effective tax rate for 2024 reflects tax effects of the Circle Health Group (Circle Health) divestiture, settlements with tax authorities and valuation allowance releases. For the full year 2025, our effective tax rate on adjusted earnings was 20.4%, compared to 23.8% in 2024. The adjusted effective tax rate for 2025 reflects the release of state uncertain tax position liabilities resulting from statute of limitations expirations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• GAAP diluted loss per share was $(13.53) for the full year 2025, driven by the goodwill impairment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Adjusted diluted earnings per share (EPS) of $2.08 for the full year 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Cash flow provided by operations for the full year 2025 was $5.1 billion, which was primarily driven by net earnings, improved pharmacy rebate timing and higher medical claims liabilities primarily driven by higher membership.

**Balance Sheet**

At December 31, 2025, the Company had cash, investments and restricted deposits of $38.8 billion and maintained $400 million of cash available for general corporate use. Medical claims liabilities totaled $20.5 billion. The Company's days in claims payable (DCP) was 46 days, a decrease of two days as compared to the third quarter of 2025, driven by the impact of state-directed payments and the elimination of the Medicare Advantage premium deficiency reserve. Total debt was $17.4 billion, which included no borrowings on the $4.0 billion Revolving Credit Facility at year end.

------

**Outlook**

Please refer to the *Forward-Looking Statements*, which should be reviewed in conjunction with the Company's 2026 outlook.

For its 2026 fiscal year, the Company's guidance is as follows.

---

| | | | |
|:---|:---|:---|:---|
| | | **Full Year 2026** | **Full Year 2026** |
| &nbsp;&nbsp;GAAP diluted EPS | &nbsp;&nbsp;GAAP diluted EPS | > $1.98 | > $1.98 |
| &nbsp;&nbsp;Adjusted diluted EPS <sup>(1)</sup> | &nbsp;&nbsp;Adjusted diluted EPS <sup>(1)</sup> | > $3.00 | > $3.00 |
| <sup>(1)</sup> | A full reconciliation of adjusted diluted EPS is shown in the Non-GAAP Financial Presentation section of this release. | A full reconciliation of adjusted diluted EPS is shown in the Non-GAAP Financial Presentation section of this release. | A full reconciliation of adjusted diluted EPS is shown in the Non-GAAP Financial Presentation section of this release. |
|  |  | **Full Year 2026** | **Full Year 2026** |
|  |  | **Low** | **High** |
| &nbsp;&nbsp;Total revenues (in billions) | &nbsp;&nbsp;Total revenues (in billions) | $186.5 | $190.5 |
| &nbsp;&nbsp;Premium and service revenues (in billions) | &nbsp;&nbsp;Premium and service revenues (in billions) | $170.0 | $174.0 |
| &nbsp;&nbsp;HBR | &nbsp;&nbsp;HBR | 90.9% | 91.7% |
| &nbsp;&nbsp;SG&A expense ratio | &nbsp;&nbsp;SG&A expense ratio | 7.1% | 7.7% |
| &nbsp;&nbsp;Adjusted SG&A expense ratio <sup>(2)</sup> | &nbsp;&nbsp;Adjusted SG&A expense ratio <sup>(2)</sup> | 7.1% | 7.7% |
| &nbsp;&nbsp;Effective tax rate | &nbsp;&nbsp;Effective tax rate | 27.0% | 28.0% |
| &nbsp;&nbsp;Adjusted effective tax rate <sup>(3)</sup> | &nbsp;&nbsp;Adjusted effective tax rate <sup>(3)</sup> | 26.0% | 27.0% |
| &nbsp;&nbsp;Diluted shares outstanding (in millions) | &nbsp;&nbsp;Diluted shares outstanding (in millions) | 495.6 | 498.6 |
| <sup>(2)</sup> | Adjusted SG&A expense ratio excludes acquisition and divestiture related expenses of approximately $300 thousand. | Adjusted SG&A expense ratio excludes acquisition and divestiture related expenses of approximately $300 thousand. | Adjusted SG&A expense ratio excludes acquisition and divestiture related expenses of approximately $300 thousand. |
| <sup>(3)</sup> | Adjusted effective tax rate excludes income tax effects of adjustments of approximately $161 million to $164 million. | Adjusted effective tax rate excludes income tax effects of adjustments of approximately $161 million to $164 million. | Adjusted effective tax rate excludes income tax effects of adjustments of approximately $161 million to $164 million. |

---

For additional guidance details, please see the 2026 Guidance Presentation referenced at Exhibit 99.2.

**Conference Call**

As previously announced, the Company will host a conference call Friday, February 6, 2026, at 9:00 a.m. ET to review the financial results for the fourth quarter and year ended December 31, 2025.

Investors and other interested parties are invited to listen to the conference call by dialing 1-877-883-0383 in the U.S. and Canada; +1-412-902-6506 from abroad, including the following Elite Entry Number: 2815529 to expedite caller registration; or via a live, audio webcast on the Company's website at <u>www.centene.com</u>, under the Investors section.

A webcast replay will be available for on-demand listening shortly following the completion of the call for the next 12 months or until 11:59 p.m. ET on Tuesday, February 9, 2027, at the aforementioned URL. In addition, a digital audio playback will be available until 9 a.m. ET on Friday, February 13, 2026, by dialing 1-877-344-7529 in the U.S., 1-855-669-9658 in Canada, or +1-412-317-0088 from abroad, and entering access code 3210284.

**Non-GAAP Financial Presentation**

The Company is providing certain non-GAAP financial measures in this release as the Company believes that these figures are helpful in allowing investors to more accurately assess the ongoing nature of the Company's operations and measure the Company's performance more consistently across periods. The Company uses the presented non-GAAP financial measures internally in evaluating the Company's performance and for planning purposes, by allowing management to focus on period-to-period changes in the Company's core business operations, and in determining employee incentive compensation. Therefore, the Company believes that this information is meaningful in addition to the information contained in the GAAP presentation of financial information. The Company strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety and cautions investors that the non-GAAP financial measures used by the Company may differ from similar measures used by other companies, even when similar terms are used to identify such measures. The presentation of non-GAAP financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP.

------

Specifically, the Company believes the presentation of non-GAAP financial measures that excludes amortization of acquired intangible assets, acquisition and divestiture related expenses, as well as other items, allows investors to develop a more meaningful understanding of the Company's core performance over time.

The tables below provide reconciliations of non-GAAP items ($ in millions, except per share data):

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| GAAP net earnings (loss) attributable to Centene | $(1101) | $283 | $(6674) | $3305 |
| &nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | 169 | 173 | 685 | 692 |
| &nbsp;&nbsp;&nbsp;Acquisition and divestiture related expenses | 3 | 7 | 4 | 82 |
| &nbsp;&nbsp;Other adjustments <sup>(1)</sup> | 513 | (20) | 7328 | (117) |
| &nbsp;&nbsp;Income tax effects of adjustments <sup>(2)</sup> | (167) | (39) | (315) | (209) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted net earnings (loss) | $(583) | $404 | $1028 | $3753 |

---

<sup>(1)</sup> Other adjustments include the following pre-tax items:

<u>2025</u>:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) for the three months ended December 31, 2025: Magellan Health impairment of $513 million, exit costs related to the wind-down of certain contracts in the Other segment of $13 million, a favorable adjustment to the gain on sale of Magellan Rx of $12 million, and net gain on debt extinguishment of $1 million;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) for the twelve months ended December 31, 2025: goodwill impairment of $6,723 million, Magellan Health impairment of $513 million, intangible asset impairment related to the wind-down of certain contracts in the Other segment of $55 million, exit costs related to the wind-down of certain contracts in the Other segment of $22 million, a net loss on real estate transactions of $18 million, a favorable adjustment to the gain on sale of Magellan Rx of $2 million and net gain on debt extinguishment of $1 million.

<u>2024</u>:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) for the three months ended December 31, 2024: gain on the sale of Collaborative Health Systems (CHS) of $17 million and net gain on the sale of property of $3 million;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) for the twelve months ended December 31, 2024: net gain on the previously reported divestiture of Magellan Specialty Health due to the achievement of contingent consideration and finalization of working capital adjustments of $83 million, net gain on the sale of property of $24 million, gain on the previously reported divestiture of Circle Health of $20 million, gain on the sale of CHS of $17 million, Health Net Federal Services asset impairment due to the 2024 final ruling on the TRICARE Managed Care Support Contract of $14 million, severance costs due to a restructuring of $13 million, an additional loss on the divestiture of our Spanish and Central European businesses of $7 million and gain on the previously reported divestiture of HealthSmart due to the finalization of working capital adjustments of $7 million.

<sup>(2)</sup> The income tax effects of adjustments are based on the effective income tax rates applicable to each adjustment. The three and twelve months ended December 31, 2025, include a tax benefit of $4 million related to tax adjustments on previously reported divestitures and impacts of the One Big Beautiful Bill Act (OBBBA). The twelve months ended December 31, 2024 include a tax benefit of $1 million related to tax adjustments on previously reported divestitures.

------

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** | **Annual Guidance** <br>**December 31, 2026** |
| | **2025** | **2024** | **2025** | **2024** | **Annual Guidance** <br>**December 31, 2026** |
| GAAP diluted earnings (loss) per share attributable to Centene | $(2.24) | $0.56 | $(13.53) | $6.31 | greater than $1.98 |
| &nbsp;&nbsp;&nbsp;Amortization of acquired intangible assets | 0.34 | 0.34 | 1.39 | 1.32 | ~$1.34 |
| &nbsp;&nbsp;&nbsp;Acquisition and divestiture related expenses | 0.01 | 0.01 | 0.01 | 0.16 | ~$— |
| &nbsp;&nbsp;Other adjustments <sup>(3)</sup> | 1.04 | (0.04) | 14.86 | (0.22) | ~$0.01 |
| &nbsp;&nbsp;Income tax effects of adjustments <sup>(4)</sup> | (0.34) | (0.07) | (0.64) | (0.40) | ~$(0.33) |
| &nbsp;&nbsp;Effect of basic to diluted shares <sup>(5)</sup> |  |  | (0.01) |  | ~$— |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted diluted earnings (loss) per share | $(1.19) | $0.80 | $2.08 | $7.17 | greater than $3.00 |

---

<sup>(3)</sup> Other adjustments include the following pre-tax items:

<u>2026</u>:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) for the twelve months ended December 31, 2026, an estimated: $0.01 per share ($0.01 after-tax) net loss on debt extinguishment.

<u>2025</u>:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) for the three months ended December 31, 2025: Magellan Health impairment of $1.04 per share ($0.79 after-tax), exit costs related to the wind-down of certain contracts in the Other segment of $0.03 per share ($0.02 after-tax), and a favorable adjustment to the gain on sale of Magellan Rx of $0.03 per share ($0.02 after-tax);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) for the twelve months ended December 31, 2025: goodwill impairment of $13.63 per share ($13.62 after-tax), Magellan Health impairment of $1.04 per share ($0.79 after-tax), intangible asset impairment related to the wind-down of certain contracts in the Other segment of $0.11 per share ($0.08 after-tax), exit costs related to the wind-down of certain contracts in the Other segment of $0.04 per share ($0.03 after-tax), a net loss on real estate transactions of $0.04 per share ($0.03 after-tax).

<u>2024</u>:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) for the three months ended December 31, 2024: gain on the sale of CHS of $0.03 per share ($0.02 after-tax) and net gain on the sale of property of $0.01 per share ($0.01 after-tax);

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) for the twelve months ended December 31, 2024: net gain on the previously reported divestiture of Magellan Specialty Health due to the achievement of contingent consideration and finalization of working capital adjustments of $0.16 per share ($0.12 after-tax), net gain on the sale of property of $0.04 per share ($0.03 after-tax), gain on the previously reported divestiture of Circle Health of $0.04 per share ($0.12 after-tax), gain on the sale of CHS of $0.03 per share ($0.02 after-tax), Health Net Federal Services asset impairment due to the 2024 final ruling on the TRICARE Managed Care Support Contract of $0.03 per share ($0.02 after-tax), severance costs due to a restructuring of $0.02 per share ($0.01 after-tax), an additional loss on the divestiture of our Spanish and Central European businesses of $0.01 per share ($0.01 after-tax) and gain on the previously reported divestiture of HealthSmart due to the finalization of working capital adjustments of $0.01 per share ($0.01 after-tax).

<sup>(4)</sup> The income tax effects of adjustments are based on the effective income tax rates applicable to each adjustment. The three and twelve months ended December 31, 2025, include a tax benefit of $0.01 related to tax adjustments on previously reported divestitures and impacts of the OBBBA.

<sup>(5)</sup> Reflects the $0.00 and $0.01 impact of using 493,042 thousand and 494,502 thousand shares in the calculation of adjusted diluted EPS for the three and twelve months ended December 31, 2025, respectively. The additional 1,509 thousand and 1,386 thousand shares for the three and twelve months ended December 31, 2025, respectively, were excluded from the calculation of the GAAP net loss per share and related adjustments due to their anti-dilutive effect.

------

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| GAAP selling, general and administrative expenses | $3370 | $3231 | $12904 | $12400 |
| Less: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Acquisition and divestiture related expenses | 3 | 7 | 4 | 82 |
| &nbsp;&nbsp;&nbsp;Restructuring costs | 13 |  | 22 | 13 |
| &nbsp;&nbsp;&nbsp;Real estate transaction costs |  |  | 2 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Adjusted selling, general and administrative expenses | $3354 | $3224 | $12876 | $12305 |

---

To provide clarity on the way management defines certain key metrics and ratios, the Company is providing a description of how the metric or ratio is calculated as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Health Benefits Ratio (HBR) (GAAP)** = Medical costs divided by premium revenues.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **SG&A Expense Ratio (GAAP)** = Selling, general and administrative expenses divided by premium and service revenues.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Adjusted SG&A Expense Ratio (non-GAAP)** = Adjusted selling, general and administrative expenses divided by premium and service revenues.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Adjusted Effective Tax Rate (non-GAAP)** = GAAP income tax expense (benefit) excluding the income tax effects of adjustments to net earnings divided by adjusted earnings (loss) before income tax expense.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Adjusted Net Earnings (non-GAAP**) = Net earnings less amortization of acquired intangible assets, less acquisition and divestiture related expenses, as well as adjustments for other items, net of the income tax effect of the adjustments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Adjusted Diluted EPS (non-GAAP)** = Adjusted net earnings divided by weighted average common shares outstanding on a fully diluted basis.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Debt to Capitalization Ratio (GAAP)** = Total debt, divided by total debt plus total stockholder's equity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Average Medical Claims Expense (GAAP)** = Medical costs for the period divided by number of days in such period. Average medical claims expense is most often calculated for the quarterly reporting period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Days in Claims Payable (GAAP)** = Medical claims liabilities divided by average medical claims expense. Days in claims payable is most often calculated for the quarterly reporting period.

In addition, the following terms are defined as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **State-directed Payments:** Payments directed by a state that have minimal risk but are administered as a premium adjustment. These payments are recorded as premium revenue and medical costs at close to a 100% HBR. In many instances, the Company has little visibility to the timing of these payments until they are paid by a state.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Pass-through Payments:** Non-risk supplemental payments from a state that the Company is required to pass through to designated contracted providers. These payments are recorded as premium tax revenue and premium tax expense.

------

**About Centene Corporation** 

Centene Corporation, a Fortune 500 company, is a leading healthcare enterprise that is committed to helping people live healthier lives. The Company takes a local approach – with local brands and local teams – to provide fully integrated, high-quality, and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured individuals. Centene offers affordable and high-quality products to more than 1 in 15 individuals across the nation, including Medicaid and Medicare members (including Medicare Prescription Drug Plans) as well as individuals and families served by the Health Insurance Marketplace.

Centene uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Centene is routinely posted and is accessible on Centene's investor relations website, https://investors.centene.com.

**Forward-Looking Statements**

*All statements, other than statements of current or historical fact, contained in this press release are forward-looking statements. Without limiting the foregoing, forward-looking statements often use words such as "believe," "anticipate," "plan," "expect," "estimate," "predict," "intend," "seek," "target," "goal," "potential," "may," "will," "would," "could," "should," "can," "continue" and other similar words or expressions (and the negative thereof). Our 2026 full year guidance outlined in the section titled "Outlook" is a forward-looking statement. Centene Corporation and its subsidiaries (Centene, the Company, our or we) intends such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we are including this statement for purposes of complying with these safe-harbor provisions. In particular, these statements include, without limitation, statements about our expected future operating or financial performance, changes in laws and regulations, market opportunity, expectations concerning pricing actions, competition, expected contract start dates and terms, expected activities in connection with completed and future acquisitions and dispositions, our investments and the adequacy of our available cash resources. These forward-looking statements reflect our current views with respect to future events and are based on numerous assumptions and assessments made by us in light of our experience and perception of historical trends, current conditions, business strategies, operating environments, future developments and other factors we believe appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties and are subject to change because they relate to events and depend on circumstances that will occur in the future, including economic, regulatory, competitive and other factors that may cause our or our industry's actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions. All forward-looking statements included in this press release are based on information available to us on the date hereof. Except as may be otherwise required by law, we undertake no obligation to update or revise the forward-looking statements included in this press release, whether as a result of new information, future events, or otherwise, after the date hereof. You should not place undue reliance on any forward-looking statements, as actual results may differ materially from projections, estimates, or other forward-looking statements due to a variety of important factors, variables and events including, but not limited to: our ability to design and price products that are competitive and/or actuarially sound; our ability to accurately predict and effectively manage health benefits and other operating expenses and reserves, including fluctuations in medical costs; rate cuts, insufficient rate changes or other payment reductions or delays by government payors affecting our government businesses; the effect of social, economic, and political conditions, geopolitical events and state and federal policies, including the amount and terms of state and federal funding for government-sponsored healthcare programs, including as a result of changes in U.S. presidential administrations or Congress; changes in federal or state laws or regulations, including changes with respect to income tax reform or government healthcare programs as well as changes with respect to the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act (collectively referred to as the ACA) and any regulations enacted thereunder, including the timing and terms of renewal or modification of the enhanced advance premium tax credits or program integrity initiatives that could have the effect of reducing membership or profitability of our products; unanticipated increased healthcare costs, including due to changes in consumer and provider behaviors, inflation and tariffs; our ability to maintain or achieve improvement in the Centers for Medicare and Medicaid Services (CMS) Star ratings and maintain or achieve improvement in other quality scores in each case that could impact revenue and future growth; competition, including for providers, broker distribution networks, contract reprocurements and organic growth; our ability to adequately anticipate demand and timely provide for operational resources to maintain service level requirements in compliance with the terms of our contracts and state and federal regulations; our ability to comply with the terms of our contracts and state and federal regulations and our ability to effectively oversee our third-party vendors to comply with the terms of their contracts with us and state and federal regulations; our ability to manage our information systems effectively; disruption, unexpected costs, or similar risks from business transactions, including acquisitions, divestitures, and changes in our relationships with third-party* 

------

*vendors; impairments to real estate, investments, goodwill and intangible assets; changes in senior management, loss of one or more key personnel or an inability to attract, hire, integrate and retain skilled personnel; membership and revenue declines or unexpected trends; changes in healthcare practices, new technologies, and advances in medicine; our ability to effectively and ethically use artificial intelligence and machine learning in compliance with applicable laws; changes in macroeconomic conditions, including inflation, interest rates and volatility in the financial markets; negative public perception of the Company and the managed care industry; uncertainty concerning government shutdowns, debt ceilings or funding; tax matters; disasters, climate-related incidents, acts of war or aggression or major epidemics; changes in expected contract start dates and terms; changes in provider, broker, vendor, state federal and other contracts and delays in the timing of regulatory approval of contracts, including due to protests and our ability to timely comply with any such changes to our contractual requirements or manage any unexpected delays in regulatory approval of contracts; the expiration, suspension, or termination of our contracts with federal or state governments (including, but not limited to, Medicaid, Medicare or other customers); the difficulty of predicting the timing or outcome of legal or regulatory audits, investigations, proceedings or matters including, but not limited to, our ability to resolve claims and/or allegations on acceptable terms, or at all, or whether additional claims, reviews or investigations will be brought; challenges to our contract awards; cyber-attacks or other data security incidents or our failure to comply with applicable privacy, data or security laws and regulations; the exertion of management's time and our resources, and other expenses incurred and business changes required in connection with complying with the terms of our contracts and the undertakings in connection with any regulatory, governmental, or third-party consents or approvals for acquisitions or dispositions; any changes in expected closing dates, estimated purchase price, or accretion for acquisitions or dispositions; losses in our investment portfolio; restrictions and limitations in connection with our indebtedness; a downgrade of our corporate family rating, issuer rating or credit rating of our indebtedness; the availability of debt and equity financing on terms that are favorable to us and risks and uncertainties discussed in the reports that Centene has filed with the Securities and Exchange Commission (SEC). This list of important factors is not intended to be exhaustive. We discuss certain of these matters more fully, as well as certain other factors that may affect our business operations, financial condition, and results of operations, in our filings with the SEC, including our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Due to these important factors and risks, we cannot give assurances with respect to our future performance, including without limitation our ability to maintain adequate premium levels or our ability to control our future medical and selling, general and administrative costs.*

------

**CENTENE CORPORATION AND SUBSIDIARIES**

**CONSOLIDATED BALANCE SHEETS**

**(In millions, except shares in thousands and per share data in dollars)**

---

| | | |
|:---|:---|:---|
| | **December 31, 2025** | **December 31, 2024** |
| | **(Unaudited)** | |
| **ASSETS** | | |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash and cash equivalents | $17888 | $14063 |
| &nbsp;&nbsp;&nbsp;Premium and trade receivables | 18105 | 19713 |
| &nbsp;&nbsp;&nbsp;Short-term investments | 2432 | 2622 |
| &nbsp;&nbsp;&nbsp;Other current assets | 1945 | 1601 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | 40370 | 37999 |
| Long-term investments | 17035 | 17429 |
| Restricted deposits | 1412 | 1390 |
| Property, software and equipment, net | 2037 | 2067 |
| Goodwill | 10835 | 17558 |
| Intangible assets, net | 4530 | 5409 |
| Other long-term assets | 528 | 593 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total assets | $76747 | $82445 |
| **LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND STOCKHOLDERS' EQUITY** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Medical claims liability | $20544 | $18308 |
| &nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | 13774 | 13174 |
| &nbsp;&nbsp;&nbsp;Return of premium payable | 1592 | 2008 |
| &nbsp;&nbsp;&nbsp;Unearned revenue | 736 | 661 |
| &nbsp;&nbsp;&nbsp;Current portion of long-term debt | 50 | 110 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | 36696 | 34261 |
| Long-term debt | 17351 | 18423 |
| Deferred tax liability | 833 | 684 |
| Other long-term liabilities | 1811 | 2567 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities | 56691 | 55935 |
| Commitments and contingencies |  |  |
| Redeemable noncontrolling interests | 23 | 10 |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;Preferred stock, $0.001 par value; authorized 10,000 shares; no shares issued or outstanding at December 31, 2025 and December 31, 2024 |  |  |
| &nbsp;&nbsp;Common stock, $0.001 par value; authorized 800,000 shares; 623,463 issued and 491,757 outstanding at December 31, 2025, and 620,195 issued and 495,907 outstanding at December 31, 2024 | 1 | 1 |
| &nbsp;&nbsp;&nbsp;Additional paid-in capital | 20777 | 20562 |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive (loss) | (58) | (504) |
| &nbsp;&nbsp;&nbsp;Retained earnings | 8674 | 15348 |
| &nbsp;&nbsp;Treasury stock, at cost (131,706 and 124,288 shares, respectively) | (9441) | (8997) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Centene stockholders' equity | 19953 | 26410 |
| &nbsp;&nbsp;&nbsp;Nonredeemable noncontrolling interest | 80 | 90 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders' equity | 20033 | 26500 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total liabilities, redeemable noncontrolling interests and stockholders' equity | $76747 | $82445 |

---

------

**CENTENE CORPORATION AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

**(In millions, except shares in thousands and per share data in dollars)**

**(Unaudited)**

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** | **2025** | **2024** |
| **Revenues:** |  |  |  |  |
| Premium | $43978 | $35519 | $171556 | $142303 |
| Service | 749 | 777 | 3025 | 3202 |
| &nbsp;&nbsp;&nbsp;Premium and service revenues | 44727 | 36296 | 174581 | 145505 |
| Premium tax | 4998 | 4509 | 20196 | 17566 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total revenues | 49725 | 40805 | 194777 | 163071 |
| **Expenses:** |  |  |  |  |
| Medical costs | 41489 | 31809 | 157702 | 125707 |
| Cost of services | 680 | 688 | 2670 | 2729 |
| Selling, general and administrative expenses | 3370 | 3231 | 12904 | 12400 |
| Depreciation expense | 160 | 141 | 590 | 549 |
| Amortization of acquired intangible assets | 169 | 173 | 685 | 692 |
| Premium tax expense | 5089 | 4588 | 20538 | 17806 |
| Impairment | 513 |  | 7311 | 13 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total operating expenses | 51470 | 40630 | 202400 | 159896 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Earnings (loss) from operations** | (1745) | 175 | (7623) | 3175 |
| **Other income (expense):** |  |  |  |  |
| Investment and other income | 369 | 344 | 1572 | 1784 |
| Debt extinguishment | 1 |  | 1 |  |
| Interest expense | (168) | (172) | (678) | (702) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Earnings (loss) before income tax** | (1543) | 347 | (6728) | 4257 |
| Income tax (benefit) expense | (443) | 67 | (51) | 963 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net earnings (loss)** | (1100) | 280 | (6677) | 3294 |
| (Earnings) loss attributable to noncontrolling interests | (1) | 3 | 3 | 11 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Net earnings (loss) attributable to Centene Corporation** | $(1101) | $283 | $(6674) | $3305 |
| **Net earnings (loss) per common share attributable to Centene Corporation:** | **Net earnings (loss) per common share attributable to Centene Corporation:** | **Net earnings (loss) per common share attributable to Centene Corporation:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic earnings (loss) per common share | $(2.24) | $0.57 | $(13.53) | $6.33 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted earnings (loss) per common share | $(2.24) | $0.56 | $(13.53) | $6.31 |
| **Weighted average number of common shares outstanding:** | **Weighted average number of common shares outstanding:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basic | 491533 | 500424 | 493116 | 521790 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Diluted | 491533 | 501978 | 493116 | 523744 |

---

------

**CENTENE CORPORATION AND SUBSIDIARIES**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(In millions, unaudited)**

---

| | | |
|:---|:---|:---|
| | **Year Ended December 31,** | **Year Ended December 31,** |
| | **2025** | **2024** |
| **Cash flows from operating activities:** |  |  |
| Net earnings (loss) | $(6677) | $3294 |
| Adjustments to reconcile net earnings (loss) to net cash provided by operating activities |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 1275 | 1241 |
| &nbsp;&nbsp;&nbsp;Stock compensation expense | 204 | 212 |
| &nbsp;&nbsp;&nbsp;Impairment | 7311 | 13 |
| &nbsp;&nbsp;&nbsp;(Gain) on debt extinguishment | (1) |  |
| &nbsp;&nbsp;&nbsp;Deferred income taxes | (60) | 13 |
| &nbsp;&nbsp;&nbsp;(Gain) loss on divestitures, net | (2) | (120) |
| &nbsp;&nbsp;&nbsp;Changes in assets and liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Premium and trade receivables | 1480 | (4333) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets | (230) | 46 |
| &nbsp;&nbsp;&nbsp;&nbsp;Medical claims liabilities | 2336 | 368 |
| &nbsp;&nbsp;&nbsp;&nbsp;Unearned revenue | 80 | (54) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable and accrued expenses | (657) | (528) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other long-term liabilities | (46) | (70) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other operating activities, net | 75 | 72 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by operating activities | 5088 | 154 |
| **Cash flows from investing activities:** |  |  |
| Capital expenditures | (767) | (644) |
| Purchases of investments | (4541) | (7183) |
| Sales and maturities of investments | 5780 | 5785 |
| Divestiture proceeds, net of divested cash |  | 990 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by (used in) investing activities | 472 | (1052) |
| **Cash flows from financing activities:** |  |  |
| Proceeds from long-term debt | 750 | 1300 |
| Payments and repurchases of long-term debt | (1895) | (622) |
| Common stock repurchases | (475) | (3124) |
| Proceeds from common stock issuances | 37 | 46 |
| Purchase of noncontrolling interest | (19) |  |
| Other financing activities, net | (19) | (6) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash (used in) financing activities | (1621) | (2406) |
| Effect of exchange rate changes on cash, cash equivalents and restricted cash |  | 8 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net increase (decrease) in cash, cash equivalents and restricted cash and cash equivalents | 3939 | (3296) |
| Cash and cash equivalents reclassified (to) from held for sale | (138) |  |
| **Cash, cash equivalents and restricted cash and cash equivalents,** beginning of period | 14156 | 17452 |
| **Cash, cash equivalents and restricted cash and cash equivalents,** end of period | $17957 | $14156 |
| Supplemental disclosures of cash flow information: |  |  |
| &nbsp;&nbsp;&nbsp;Interest paid | $647 | $688 |
| &nbsp;&nbsp;&nbsp;Income taxes paid, net | $448 | $1002 |
| The following table provides a reconciliation of cash, cash equivalents and restricted cash and cash equivalents reported within the Consolidated Balance Sheets to the totals above: | The following table provides a reconciliation of cash, cash equivalents and restricted cash and cash equivalents reported within the Consolidated Balance Sheets to the totals above: | The following table provides a reconciliation of cash, cash equivalents and restricted cash and cash equivalents reported within the Consolidated Balance Sheets to the totals above: |
|  | **December 31,** | **December 31,** |
|  | **2025** | **2024** |
| Cash and cash equivalents | $17888 | $14063 |
| Restricted cash and cash equivalents, included in restricted deposits | 69 | 93 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total cash, cash equivalents and restricted cash and cash equivalents | $17957 | $14156 |

---

------

**CENTENE CORPORATION**

**SUPPLEMENTAL FINANCIAL DATA**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | **Q4**<br>**2025** | **Q3**<br>**2025** | **Q2**<br>**2025** | **Q1**<br>**2025** | **Q4**<br>**2024** |
| **MEMBERSHIP** | **MEMBERSHIP** |  |  |  |  |  |
| Traditional Medicaid <sup>(1)</sup> | Traditional Medicaid <sup>(1)</sup> | 10932600 | 11115400 | 11227400 | 11369400 | 11408100 |
| High Acuity Medicaid <sup>(2)</sup> | High Acuity Medicaid <sup>(2)</sup> | 1585800 | 1591000 | 1592300 | 1589400 | 1595400 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Medicaid | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Medicaid | 12518400 | 12706400 | 12819700 | 12958800 | 13003500 |
| Marketplace | Marketplace | 5541400 | 5828100 | 5862800 | 5626000 | 4382100 |
| Individual and Commercial Group <sup>(3)</sup> | Individual and Commercial Group <sup>(3)</sup> | 452500 | 447900 | 449700 | 448200 | 431400 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Commercial | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total Commercial | 5993900 | 6276000 | 6312500 | 6074200 | 4813500 |
| Medicare <sup>(4)</sup> | Medicare <sup>(4)</sup> | 1002600 | 1013200 | 1026900 | 1043200 | 1110900 |
| Medicare PDP | Medicare PDP | 8118600 | 7972500 | 7845800 | 7867800 | 6925700 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total at-risk membership | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total at-risk membership | 27633500 | 27968100 | 28004900 | 27944000 | 25853600 |
| TRICARE eligibles | TRICARE eligibles |  |  |  |  | 2747000 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | 27633500 | 27968100 | 28004900 | 27944000 | 28600600 |
| <sup>(1)</sup> | Membership includes TANF, Medicaid Expansion, CHIP, Foster Care and Behavioral Health. | Membership includes TANF, Medicaid Expansion, CHIP, Foster Care and Behavioral Health. | Membership includes TANF, Medicaid Expansion, CHIP, Foster Care and Behavioral Health. | Membership includes TANF, Medicaid Expansion, CHIP, Foster Care and Behavioral Health. | Membership includes TANF, Medicaid Expansion, CHIP, Foster Care and Behavioral Health. | Membership includes TANF, Medicaid Expansion, CHIP, Foster Care and Behavioral Health. |
| <sup>(2)</sup> | Membership includes ABD, IDD, LTSS and MMP Duals. | Membership includes ABD, IDD, LTSS and MMP Duals. | Membership includes ABD, IDD, LTSS and MMP Duals. | Membership includes ABD, IDD, LTSS and MMP Duals. | Membership includes ABD, IDD, LTSS and MMP Duals. | Membership includes ABD, IDD, LTSS and MMP Duals. |
| <sup>(3)</sup> | Membership includes Commercial Group, ICHRA and Other Off-Exchange Individual. | Membership includes Commercial Group, ICHRA and Other Off-Exchange Individual. | Membership includes Commercial Group, ICHRA and Other Off-Exchange Individual. | Membership includes Commercial Group, ICHRA and Other Off-Exchange Individual. | Membership includes Commercial Group, ICHRA and Other Off-Exchange Individual. | Membership includes Commercial Group, ICHRA and Other Off-Exchange Individual. |
| <sup>(4)</sup> | Membership includes Medicare Advantage and Medicare Supplement. | Membership includes Medicare Advantage and Medicare Supplement. | Membership includes Medicare Advantage and Medicare Supplement. | Membership includes Medicare Advantage and Medicare Supplement. | Membership includes Medicare Advantage and Medicare Supplement. | Membership includes Medicare Advantage and Medicare Supplement. |
| **NUMBER OF EMPLOYEES** | **NUMBER OF EMPLOYEES** | 61100 | 60900 | 60300 | 60400 | 60500 |
| **DAYS IN CLAIMS PAYABLE** | **DAYS IN CLAIMS PAYABLE** | 46 | 48 | 47 | 49 | 53 |
| **CASH, INVESTMENTS AND RESTRICTED DEPOSITS (in millions)** | **CASH, INVESTMENTS AND RESTRICTED DEPOSITS (in millions)** | **CASH, INVESTMENTS AND RESTRICTED DEPOSITS (in millions)** | **CASH, INVESTMENTS AND RESTRICTED DEPOSITS (in millions)** | **CASH, INVESTMENTS AND RESTRICTED DEPOSITS (in millions)** | **CASH, INVESTMENTS AND RESTRICTED DEPOSITS (in millions)** | **CASH, INVESTMENTS AND RESTRICTED DEPOSITS (in millions)** |
| Regulated | Regulated | $37289 | $37574 | $36403 | $35922 | $34433 |
| Unregulated | Unregulated | 1478 | 1259 | 1086 | 1042 | 1071 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total | $38767 | $38833 | $37489 | $36964 | $35504 |
| **DEBT TO CAPITALIZATION** | **DEBT TO CAPITALIZATION** | 46.5% | 45.5% | 39.0% | 39.5% | 41.2% |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **OPERATING RATIOS** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2025** | **2024** | **2025** | **2024** |
| HBR | 94.3% | 89.6% | 91.9% | 88.3% |
| SG&A expense ratio | 7.5% | 8.9% | 7.4% | 8.5% |
| Adjusted SG&A expense ratio | 7.5% | 8.9% | 7.4% | 8.5% |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **HBR BY PRODUCT** | **HBR BY PRODUCT** | **Three Months Ended December 31,** | **Three Months Ended December 31,** | **Year Ended December 31,** | **Year Ended December 31,** |
|  |  | **2025** | **2024** | **2025** | **2024** |
| Medicaid | Medicaid | 93.0% | 93.4% | 93.7% | 92.5% |
| Commercial | Commercial | 95.4% | 81.8% | 87.9% | 77.3% |
| Medicare <sup>(5)</sup> | Medicare <sup>(5)</sup> | 96.1% | 86.7% | 92.0% | 88.7% |
| <sup>(5)</sup> | Medicare includes Medicare Advantage, Medicare PDP and Medicare Supplement. | Medicare includes Medicare Advantage, Medicare PDP and Medicare Supplement. | Medicare includes Medicare Advantage, Medicare PDP and Medicare Supplement. | Medicare includes Medicare Advantage, Medicare PDP and Medicare Supplement. | Medicare includes Medicare Advantage, Medicare PDP and Medicare Supplement. |

---

------

**MEDICAL CLAIMS LIABILITY** 

The changes in medical claims liability are summarized as follows (in millions):

---

| | |
|:---|:---|
| **Balance, December 31, 2024** | $18308 |
| &nbsp;&nbsp;&nbsp;Less: Reinsurance recoverables | 65 |
| Balance, December 31, 2024, net | 18243 |
| Incurred related to: |  |
| &nbsp;&nbsp;&nbsp;Current period | 160109 |
| &nbsp;&nbsp;&nbsp;Prior periods | (2315) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total incurred | 157794 |
| Paid related to: |  |
| &nbsp;&nbsp;&nbsp;Current period | 140691 |
| &nbsp;&nbsp;&nbsp;Prior periods | 14677 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total paid | 155368 |
| Plus: Premium deficiency reserve | (92) |
| Plus: Divestitures | (109) |
| Balance, December 31, 2025, net | 20468 |
| &nbsp;&nbsp;&nbsp;Plus: Reinsurance recoverables | 76 |
| **Balance, December 31, 2025** | $20544 |

---

Centene's claims reserving process utilizes a consistent actuarial methodology to estimate Centene's ultimate liability. Any reduction in the "Incurred related to: Prior periods" amount may be offset as Centene actuarially determines the "Incurred related to: Current period." Additionally, approximately $93 million was recorded as a reduction to premium revenues resulting from development within "Incurred related to: Prior periods" due to minimum HBR and other return of premium programs.

The amount of the "Incurred related to: Prior periods" above represents favorable development and includes the effects of reserving under moderately adverse conditions, new markets where we use a conservative approach in setting reserves during the initial periods of operations, receipts from other third-party payors related to coordination of benefits and lower medical utilization and cost trends for dates of service December 31, 2024, and prior.

## Exhibit 99.2

![](centenecorporation2026gu001.jpg)

CENTENE CORPORATION 2026 GUIDANCE FEBRUARY 2026 Exhibit 99.2

------

![](centenecorporation2026gu002.jpg)

2 All statements, other than statements of current or historical fact, contained in this presentation are forward-looking statements. Without limiting the foregoing, forward-looking statements often use words such as "guidance," "believe," "anticipate," "plan," "expect," "estimate," "predict," "intend," "seek," "target," "goal," "potential," "may," "will," "would," "could," "should," "can," "continue" and other similar words or expressions (and the negative thereof). All guidance and related disclosure in this presentation are forward-looking statements. Centene Corporation and its subsidiaries (Centene, the Company, our or we) intends such forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we are including this statement for purposes of complying with these safe-harbor provisions. In particular, these statements include, without limitation, statements about our expected future operating or financial performance, changes in laws and regulations, market opportunity, expectations concerning pricing actions, competition, expected contract start dates and terms, expected activities in connection with completed and future acquisitions and dispositions, our investments and the adequacy of our available cash resources. These forward-looking statements reflect our current views with respect to future events and are based on numerous assumptions and assessments made by us in light of our experience and perception of historical trends, current conditions, business strategies, operating environments, future developments and other factors we believe appropriate. By their nature, forward-looking statements involve known and unknown risks and uncertainties and are subject to change because they relate to events and depend on circumstances that will occur in the future, including economic, regulatory, competitive and other factors that may cause our or our industry's actual results, performance or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions. All forward-looking statements included in this presentation are based on information available to us on the date hereof. Except as may be otherwise required by law, we undertake no obligation to update or revise the forward-looking statements included in this presentation, whether as a result of new information, future events or otherwise, after the date hereof. You should not place undue reliance on any forward-looking statements, as actual results may differ materially from projections, estimates, or other forward-looking statements due to a variety of important factors, variables and events including, but not limited to: our ability to design and price products that are competitive and/or actuarially sound; our ability to accurately predict and effectively manage health benefits and other operating expenses and reserves, including fluctuations in medical costs; rate cuts, insufficient rate changes or other payment reductions or delays by government payors affecting our government businesses; the effect of social, economic, and political conditions, geopolitical events and state and federal policies, including the amount and terms of state and federal funding for government-sponsored healthcare programs, including as a result of changes in U.S. presidential administrations or Congress; changes in federal or state laws or regulations, including changes with respect to income tax reform or government healthcare programs as well as changes with respect to the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act (collectively referred to as the ACA) and any regulations enacted thereunder, including the timing and terms of renewal or modification of the enhanced advance premium tax credits or program integrity initiatives that could have the effect of reducing membership or profitability of our products; unanticipated increased healthcare costs, including due to changes in consumer and provider behaviors, inflation and tariffs; our ability to maintain or achieve improvement in the Centers for Medicare and Medicaid Services (CMS) Star ratings and maintain or achieve improvement in other quality scores in each case that could impact revenue and future growth; competition, including for providers, broker distribution networks, contract reprocurements and organic growth; our ability to adequately anticipate demand and timely provide for operational resources to maintain service level requirements in compliance with the terms of our contracts and state and federal regulations; our ability to comply with the terms of our contracts and state and federal regulations and our ability to effectively oversee our third-party vendors to comply with the terms of their contracts with us and state and federal regulations; our ability to manage our information systems effectively; disruption, unexpected costs, or similar risks from business transactions, including acquisitions, divestitures, and changes in our relationships with third-party vendors; impairments to real estate, investments, goodwill and intangible assets; changes in senior management, loss of one or more key personnel or an inability to attract, hire, integrate and retain skilled personnel; membership and revenue declines or unexpected trends; changes in healthcare practices, new technologies, and advances in medicine; our ability to effectively and ethically use artificial intelligence and machine learning in compliance with applicable laws; changes in macroeconomic conditions, including inflation, interest rates and volatility in the financial markets; negative public perception of the Company and the managed care industry; uncertainty concerning government shutdowns, debt ceilings or funding; tax matters; disasters, climate-related incidents, acts of war or aggression or major epidemics; changes in expected contract start dates and terms; changes in provider, broker, vendor, state federal and other contracts and delays in the timing of regulatory approval of contracts, including due to protests and our ability to timely comply with any such changes to our contractual requirements or manage any unexpected delays in regulatory approval of contracts; the expiration, suspension, or termination of our contracts with federal or state governments (including, but not limited to, Medicaid, Medicare or other customers); the difficulty of predicting the timing or outcome of legal or regulatory audits, investigations, proceedings or matters including, but not limited to, our ability to resolve claims and/or allegations on acceptable terms, or at all, or whether additional claims, reviews or investigations will be brought; challenges to our contract awards; cyber-attacks or other data security incidents or our failure to comply with applicable privacy, data or security laws and regulations; the exertion of management's time and our resources, and other expenses incurred and business changes required in connection with complying with the terms of our contracts and the undertakings in connection with any regulatory, governmental, or third-party consents or approvals for acquisitions or dispositions; any changes in expected closing dates, estimated purchase price, or accretion for acquisitions or dispositions; losses in our investment portfolio; restrictions and limitations in connection with our indebtedness; a downgrade of our corporate family rating, issuer rating or credit rating of our indebtedness; the availability of debt and equity financing on terms that are favorable to us and risks and uncertainties discussed in the reports that Centene has filed with the Securities and Exchange Commission (SEC). This list of important factors is not intended to be exhaustive. We discuss certain of these matters more fully, as well as certain other factors that may affect our business operations, financial condition and results of operations, in our filings with the SEC, including our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. Due to these important factors and risks, we cannot give assurances with respect to our future performance, including without limitation our ability to maintain adequate premium levels or our ability to control our future medical and selling, general and administrative costs. The guidance in this presentation is only effective as of the date given and will not be updated or affirmed unless and until we publicly announce updated or affirmed guidance. Included in this presentation are certain non-GAAP financial measures. Please see the Appendix for reconciliations to the most directly comparable GAAP measures. Forward-Looking Statements

------

![](centenecorporation2026gu003.jpg)

3 $7.5 $0 2026 Premium & Service Revenue Guidance ($ IN BILLIONS) Medicaid $88 $34.5 $45 $4.5 M e d ic a id C o m m e rc ia l M e d ic a re O th e r Marketplace Medicare Advantage $174.6 $172.0 2026 Estimated Segment Premium & Service Revenue1 1 2026 Estimated Premium & Service Revenues are reflected at the guidance mid-point. 2026 Guidance Mid-point 2025 Actual Medicare PDP ($8.1) ($2.0)

------

![](centenecorporation2026gu004.jpg)

4 2026 HBR Guidance 88.3% - 88.5% 2025 Actual Commercial Medicaid Medicare 2026 Guidance Mid-point ~0 bps ~(95) bps 91.9% ~+35 bps 91.3% Segment impact on consolidated HBR at the mid-point 1 Represents an increase in Medicare Prescription Drug Plans (PDP) HBR net of Medicare Advantage improvement. 1

------

![](centenecorporation2026gu005.jpg)

5 2026 Guidance Low High Total Revenues (in billions) $186.5 $190.5 Premium & Service Revenues (in billions) $170.0 $174.0 GAAP Diluted Earnings Per Share (EPS) > $1.98 Adjusted Diluted EPS1 > $3.00 HBR 90.9% 91.7% SG&A Expense Ratio 7.1% 7.7% Adjusted SG&A Expense Ratio1 7.1% 7.7% Effective Tax Rate 27.0% 28.0% Adj. Effective Tax Rate1 26.0% 27.0% Diluted Shares Outstanding (in millions) 495.6 498.6 1 Adjusted Diluted EPS, Adjusted SG&A Expense Ratio and Adjusted Effective Tax Rate are non-GAAP financial measures. Please see the Appendix for further information on these forward-looking non-GAAP financial measures, including a full reconciliation for Adjusted Diluted EPS to the most directly comparable GAAP measure, GAAP Diluted EPS.

------

![](centenecorporation2026gu006.jpg)

6 2 3 Investment and other income of ~$1.4 billion; 5 4 Additional 2026 Assumptions Cost of services expense ratio of 91.4% to 92.0% Capital expenditures of ~$800 million; Depreciation expense of $580 million to $600 million 1 Continued emphasis on debt reduction Interest expense of $620 million to $650 million Medicaid net rate increase impact in the mid-4%s

------

![](centenecorporation2026gu007.jpg)

7 2026 Guidance GAAP diluted EPS attributable to Centene > $1.98 Amortization of acquired intangible assets ~$1.34 Acquisition and divestiture related expenses ~$⸺ Other adjustments1 ~$0.01 Income tax effects of adjustments2 ~($0.33) Adjusted diluted EPS > $3.00 1 Other adjustments include the following pre-tax items: loss on debt extinguishment of $0.01 per share ($0.01 after-tax). 2 The income tax effects of adjustments are based on the effective income tax rates applicable to each adjustment. RECONCILIATION OF GAAP DILUTED EPS TO ADJUSTED DILUTED EPS Reconciliation of Non-GAAP Financial Measures Included in this presentation are certain non-GAAP financial measures. Management believes that non-GAAP financial measures provide information that is useful to investors in understanding period-over-period operating results and enhance the ability of investors to analyze Centene's business trends and performance. The non-GAAP financial measures should not be considered in isolation, or as a substitute for the most directly comparable GAAP financial measure and may not be comparable to similar measures used by other companies. The Company strongly encourages investors to review its consolidated financial statements and publicly filed reports in their entirety. Non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. The Company references Adjusted SG&A Expense Ratio guidance, which excludes acquisition and divestiture related expenses and other items. The 2026 Adjusted SG&A Expense Ratio excludes estimated acquisition and divestiture related costs of approximately $300 thousand. The Company also references Adjusted Effective Tax Rate guidance, which excludes amortization of acquired intangible assets. The 2026 Adjusted Effective Tax Rate excludes income tax effects of adjustments of approximately $161 million to $164 million. A reconciliation of Adjusted Diluted EPS to the most directly comparable GAAP financial measure is included for reference.

------